Polaryx Therapeutics (PLYX) Total Current Liabilities (2024 - 2026)
Polaryx Therapeutics (PLYX) posted quarterly Total Current Liabilities of $1.0 million for Q1 2026, up 67.6% quarter-over-quarter from $605000.0 in Q4 2025.
Polaryx Therapeutics (PLYX) Total Current Liabilities (2024 - 2026) Analysis & Trends
Polaryx Therapeutics (PLYX) has reported Total Current Liabilities for 3 consecutive years, with $1.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities changed N/A year-over-year to $1.0 million; the TTM figure through Mar 2026 stood at $1.0 million (changed N/A YoY), while the FY2025 annual figure was $605000.0, up 109.34% from the prior year.
- Total Current Liabilities advanced to $1.0 million in Q1 2026 per PLYX's latest filing, from $605000.0 in the prior quarter.
- Across five years, Total Current Liabilities topped out at $1.0 million in Q1 2026 and bottomed at $289000.0 in Q4 2024.
- Historically, Total Current Liabilities has averaged $636000.0 across 3 years, with a median of $605000.0 in 2025.
- On a YoY basis, Total Current Liabilities climbed as much as 109.34% in 2025 and fell as far as 109.34% in 2025.
- Polaryx Therapeutics' Total Current Liabilities stood at $289000.0 in 2024, then surged by 109.34% to $605000.0 in 2025, then surged by 67.6% to $1.0 million in 2026.
- Business Quant data shows PLYX's Total Current Liabilities at $1.0 million in Q1 2026, $605000.0 in Q4 2025, and $289000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | Polaryx Therapeutics | 102.35 Mn | 90.81 Mn | - | 873,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 873,000.00 |
| Mar 31, 2026 | 1.01 Mn |
| Dec 31, 2025 | 605,000.00 |
| Dec 31, 2024 | 289,000.00 |